How long you can stay on Zoladex depends entirely on the condition being treated. For endometriosis and fibroids, the limit is typically 6 months. For prostate cancer, treatment is often indefinite. For breast cancer, the standard course runs about 2 years. Each of these timelines exists for specific reasons tied to the drug’s benefits and risks at different durations.
Prostate Cancer: Often Indefinite
For advanced prostate cancer, Zoladex is designed for long-term use. The FDA prescribing label states it is “intended for long-term administration unless clinically inappropriate.” In practice, this means many men stay on Zoladex for years, and some remain on it indefinitely as long as the cancer responds and side effects remain manageable.
That open-ended timeline comes with real trade-offs. Men using Zoladex or similar hormone-suppressing drugs face a 42% higher risk of developing diabetes and a 16% higher risk of coronary heart disease compared to men not on this type of therapy. After at least one year of treatment, cardiovascular risk rises by about 20%. The underlying reasons include changes in how the body handles insulin, increases in cholesterol (total cholesterol rises roughly 9%, triglycerides by nearly 27%), and a tendency toward weight gain. These risks apply whether someone has been on treatment for months or years, which is why regular metabolic monitoring matters for anyone on long-term Zoladex.
Endometriosis: 6 Months Maximum
For endometriosis, the recommended course is 6 months for women 18 and older. The FDA caps it there because no clinical data exist on the effects of treating benign gynecological conditions with Zoladex beyond that point. Retreatment is not officially recommended either, since safety data for repeat courses haven’t been established.
The main concern driving that limit is bone loss. After 6 months of Zoladex, women lose an average of 4.3% of their spinal bone density. A 12-month study in women over 40 found even steeper losses: 4.4% at the spine, 7.5% at the femoral neck, and 7.6% at the hip. Zoladex works by suppressing estrogen, and estrogen is essential for maintaining bone strength. The longer you suppress it, the more bone you lose, and that loss may not fully reverse after stopping treatment.
If endometriosis symptoms return and your doctor considers another course, bone density monitoring with a scan becomes an important step before restarting.
How Add-Back Therapy Can Extend Treatment
Some clinical protocols allow Zoladex use for up to 24 months when paired with what’s called add-back therapy. This involves taking a low dose of hormones alongside Zoladex to protect against hot flashes and bone loss. The hormone dose is kept low enough that it won’t stimulate endometriosis growth but high enough to preserve bone density and reduce side effects. This approach is used in specialized settings and requires close oversight, but it can be an option when shorter courses haven’t provided enough relief.
Uterine Fibroids: 6 Months or Less
When Zoladex is used to shrink fibroids before surgery, the maximum recommended duration is 6 months. In many cases, the actual treatment period is shorter, since the goal is simply to reduce fibroid size enough to make surgery easier or less invasive. The same bone density concerns that apply to endometriosis treatment apply here. Fibroids typically regrow after stopping Zoladex, so it’s used as a bridge to a procedure rather than a standalone solution.
Breast Cancer: Typically 2 Years
For premenopausal women with early-stage breast cancer, the standard adjuvant course of Zoladex is 2 years, given as an injection every 4 weeks. The ZIPP trial, one of the largest studies on this use, found that 2 years of Zoladex was as effective as 2 years of tamoxifen when outcomes were measured 15 years later. Some oncologists prescribe longer courses of ovarian suppression (up to 5 years) depending on cancer risk factors, but the trial that established the 2-year benchmark did not specifically test whether longer durations offer additional benefit.
Bone Loss Is the Central Concern
Across all conditions, bone density loss is the primary factor limiting how long you can safely stay on Zoladex. The drug works by shutting down sex hormone production, and those hormones play a direct role in maintaining bone strength. For short courses of a few months, bone density generally recovers after treatment ends. For longer courses, especially in prostate cancer patients who may be on the drug for years, the cumulative loss can become significant enough to increase fracture risk.
If you’re on Zoladex for more than 6 months, periodic bone density scans help track whether your bones are thinning at a rate that needs intervention. Weight-bearing exercise and calcium and vitamin D intake can help offset some of the loss, though they won’t fully prevent it. For men on long-term treatment, the combination of bone loss, metabolic changes, and cardiovascular risk means that the decision to continue Zoladex involves regularly weighing its cancer-fighting benefits against its cumulative side effects.